

S10 Table. Clinical characteristics of ERG, LRG and NRG among *EGFR*-mutant stage IB (AJCC 7th edition) patients (n=203)

Characteristic	ERG (n=9)	LRG (n=31)	NRG (n=160)	p-value
Age (yr)				0.420
≤ 65	7 (77.8)	16 (51.6)	86 (53.8)	
> 65	2 (22.2)	15 (48.4)	74 (46.2)	0.921
BMI (kg/m²)	24.41±4.80	23.83±2.73	24.00±3.32	
Sex				0.891
Male	4 (44.4)	10 (32.3)	62 (38.8)	
Female	5 (55.6)	21 (67.7)	98 (61.3)	
Smoking status				0.581
Never	3 (33.3)	22 (71.0)	99 (61.9)	
Ever	6 (66.7)	9 (29.0)	61 (38.1)	
Unknown	0	0	0	
ECOG				0.856
0-1	5 (55.6)	25 (80.6)	128 (80.0)	
≥ 2	2 (22.2)	1 (3.2)	3 (1.9)	
Unknown	2 (22.2)	5 (16.1)	29 (18.1)	
PFT				
FVC (L)	2.93±0.82	3.02±0.80	3.30±0.79	0.153
FEV1 (L)	2.29±0.71	2.31±0.54	2.49±0.61	0.279
DLco (%)	87.00±27.58	88.25±16.68	94.51±21.57	0.218
Surgery type				0.380
Wedge resection	1 (11.1)	1 (3.2)	3 (1.9)	
Segmentectomy	0	1 (3.2)	9 (5.6)	
Lobectomy	8 (88.9)	29 (93.5)	146 (91.2)	
Pneumonectomy	0	0	2 (1.2)	
Histologic type				0.753
Squamous	0	1 (3.2)	7 (4.4)	
Adenocarcinoma	9 (100)	29 (93.5)	151 (94.4)	
Adenosquamous	0	0	0	
Others	0	1 (3.2)	2 (1.2)	
Pleural invasion				0.061
None (PL0)	3 (33.3)	7 (22.6)	87 (54.4)	
Visceral pleural invasion (PL1)	6 (66.7)	21 (67.7)	58 (36.2)	
Invasion to the surface of the visceral pleura (PL2)	0	3 (9.7)	15 (9.4)	
Extend to the parietal pleura (PL3)	0	0	0	
Unknown	0	0	0	
Mediastinal LN resection				0.422
No	1 (11.1)	1 (3.2)	6 (3.8)	
Sampling	0	2 (6.5)	7 (4.4)	
Dissection	8 (88.9)	28 (90.3)	146 (91.2)	
Unknown	0	0	1 (0.6)	
ALK				0.442
Positive	1 (11.1)	0	7 (4.4)	
Negative	7 (77.8)	27 (87.1)	124 (77.5)	
unknown	1 (11.1)	4 (12.9)	29 (18.1)	
Chemotherapy				< 0.001
Adjuvant	8 (88.9)	21 (67.7)	36 (22.5)	
None	1 (11.1)	10 (32.3)	124 (77.5)	
RT				< 0.001

Adjuvant	5 (55.6)	7 (22.6)	6 (3.8)	
None	4 (44.4)	24 (77.4)	154 (96.2)	
Observation time (mo)	29.63±10.74	35.35±7.49	38.71±11.80	0.025
Recurrence-free survival time (mo)	10.35±3.21	26.91±7.93	38.97±11.62	< 0.001

Values are presented as number (%) or mean±SD. The significance level of p-value was set after Bonferroni correction. AJCC, American Joint Commission on Cancer; ALK, anaplastic lymphoma kinase; ALK positive, ALK IHC or FISH positive; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; ERG, early recurrence group; PFT, pulmonary function test; DLco, diffusing capacity of the lungs for carbon monoxide; EGFR, epidermal growth factor receptor; FEV₁, forced expiratory volume exhaled in the first second; FVC, forced vital capacity; LRG, late recurrence group; NOS, not otherwise specified; NRG, no recurrence group; RT, radiotherapy.